In this study, we demonstrated that BRD4 is upregulated in CLL-associated MDSCs and pharmacological inhibition with the novel BET inhibitor, OPN5, alleviated MDSC-mediated immune-suppression in ex vivo and in vivo settings. The gene discussed is BRD4; the disease is B-cell chronic lymphocytic leukemia.